secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0000950170-25-036296
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenaya Therapeutics reports Q4 2024 net loss of $23.8M; cash runway extended to mid-2026 after $48.9M offering
--------------------------------------------------------------------------------

- Net loss of $23.8M ($0.28 per share) for Q4 2024; full-year net loss $111.1M ($1.31 per share).
- Cash and investments $61.4M at Dec 31, 2024; after $48.9M March 2025 offering, runway into mid-2026.
- Dosing initiated in Cohort 2 (6E13 vg/kg) of MyPEAK-1 Phase 1b/2 trial for TN-201; Cohort 1 data accepted as ACC late-breaker.
- First patient dosed in RIDGE-1 Phase 1b trial for TN-401; initial data expected in 2H25; CIRM awarded $8M grant.
- Hiro Higa promoted to SVP, Finance and interim principal accounting officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000095017025036296/0000950170-25-036296-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000095017025036296/tnya-20250310.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-036296

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer